Bioqual (OTCMKTS:BIOQ – Get Free Report) announced its quarterly earnings data on Monday. The company reported ($2.81) EPS for the quarter, Zacks reports. Bioqual had a negative net margin of 2.27% and a negative return on equity of 2.69%. The firm had revenue of $9.27 million during the quarter.
Bioqual Price Performance
Shares of BIOQ opened at $33.00 on Wednesday. Bioqual has a one year low of $32.50 and a one year high of $43.55. The company has a market cap of $29.37 million, a PE ratio of -8.73 and a beta of -0.20. The stock has a 50-day moving average of $32.70 and a 200-day moving average of $34.38.
Bioqual Company Profile
Bioqual, Inc is a contract research organization that provides preclinical biomedical research services to pharmaceutical, biotechnology and government customers. The company specializes in infectious disease research and uses laboratory and animal models to support the development and evaluation of vaccines, therapeutics and diagnostic products.
Its services have included studies involving HIV, hepatitis, influenza, COVID-19 and other infectious diseases, as well as immunology, pharmacology and toxicology research.
Featured Articles
- Five stocks we like better than Bioqual
- Meta’s Muse Highlights Arm’s Growing Role in AI Infrastructure
- Oura’s $15.6 Billion IPO Is Betting Investors See More Than a Smart Ring
- AMD Chips Away at NVIDIA’s AI Throne
- Is the Fed Playing Chess With Rates—Or Just Behind the Curve Again?
Receive News & Ratings for Bioqual Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bioqual and related companies with MarketBeat.com's FREE daily email newsletter.
